Health Care • Biotechnology: Pharmaceutical Preparations
$27.12 ▼ -0.14
(-0.51%)
MKT CAP: $2.96B • VOL: 2.38M
52W L $12 52W H $28
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$23
MEDIAN
$30
MEAN
$31
HIGH
$37
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE NRIX TAPE
NRIX // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $32.82 | $31.19 | 2025-02-14 | $24.68 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $34.17 | $32.00 | 2025-02-06 | $25.49 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $30.92 | $29.83 | 2025-01-29 | $26.04 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $27.66 | — | 2025-01-17 | $26.58 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $23.87 | $25.76 | 2025-01-09 | $24.14 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $32.27 | $28.20 | 2024-12-18 | $23.59 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $26.31 | $27.39 | 2024-12-04 | $25.22 | -4.3% | 48% | C |